Prognostic significance of AKR1B10 gene expression in hepatocellular carcinoma and surrounding non-tumorous liver tissue.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Oncology Letters

• Publication date

  2016-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3892/ol.2016.5240PMID 28105190PMCID PMC5228455
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Molecular Diagnostics

  2016cited by this paper
• Expression of Aldo-Keto Reductase Family 1 Member B10 in the Early Stages of Human Hepatocarcinogenesis

  2014cited by this paper
• Knockdown or inhibition of aldo-keto reductase 1B10 inhibits pancreatic carcinoma growth via modulating Kras-E-cadherin pathway.

  2014cited by this paper
• Aldoketoreductase family 1B10 (AKR1B10) as a biomarker to distinguish hepatocellular carcinoma from benign liver lesions.

  2014cited by this paper
• Adjuvant therapy for hepatocellular carcinoma: current situation and prospect.

  2013cited by this paper
• Enhanced Expression of Long Non-Coding RNA HOTAIR Is Associated with the Development of Gastric Cancer

  2013cited by this paper
• Up-regulated aldo-keto reductase family 1 member B10 in chronic hepatitis C: association with serum alpha-fetoprotein and hepatocellular carcinoma

  2012cited by this paper
• AKR1B10 expression is associated with less aggressive hepatocellular carcinoma: a clinicopathological study of 168 cases

  2011cited by this paper
• Hepatocellular Carcinoma: Current Management and Perspectives for the Future

  2011cited by this paper
• AKR1B10 is Associated with Smoking and Smoking-Related Non-Small-Cell Lung Cancer

  2011cited by this paper
• Identification and expression analysis of the aldo-ketoreductase1-B10 gene in primary malignant liver tumours.

  2010cited by this paper
• Gene expression analysis using agilent DNA microarrays.

  2009cited by this paper
• Comparison of Recurrence of Hepatocellular Carcinoma After Resection in Patients with Cirrhosis to Its Occurrence in a Surveilled Cirrhotic Population

  2009cited by this paper
• A Prospective Randomized Trial Comparing Percutaneous Local Ablative Therapy and Partial Hepatectomy for Small Hepatocellular Carcinoma

  2006cited by this paper
• Early and Late Recurrence After Liver Resection for Hepatocellular Carcinoma: Prognostic and Therapeutic Implications

  2006cited by this paper
• Implication of Frequent Local Ablation Therapy for Intrahepatic Recurrence in Prolonged Survival of Patients With Hepatocellular Carcinoma Undergoing Hepatic Resection: An Analysis of 610 Patients Over 16 Years Old

  2006cited by this paper
• Results of 404 hepatic resections including 80 repeat hepatectomies for hepatocellular carcinoma.

  2006cited by this paper
• Global Cancer Statistics, 2002

  2005cited by this paper
• Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy.

  2003cited by this paper
• Diagnosis of intrahepatic metastasis and multicentric carcinogenesis by microsatellite loss of heterozygosity in patients with multiple and recurrent hepatocellular carcinomas.

  2003cited by this paper
• Mitochondrial D-loop mutations as clonal markers in multicentric hepatocellular carcinoma and plasma.

  2002cited by this paper
• Prognostic factors after hepatic resection for hepatocellular carcinoma with hepatitis C viral infection: univariate and multivariate analysis

  2001cited by this paper
• Surgical treatment of recurrent hepatocellular carcinoma based on the mode of recurrence: repeat hepatic resection or ablation are good choices for patients with recurrent multicentric cancer.

  2001cited by this paper
• Identification and Characterization of a Novel Human Aldose Reductase-like Gene*

  1998cited by this paper
• Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma

  1997cited by this paper
• Quantification of mRNA using competitive RT-PCR with standard-curve methodology.

  1996cited by this paper
• Prognostic factors of hepatocellular carcinoma in patients undergoing hepatic resection.

  1994cited by this paper
• Possible multicentric occurrence of hepatocellular carcinoma: A clinicopathological study

  1994cited by this paper
• Long-term results after resection of hepatocellular carcinoma: experience of 480 cases.

  1993cited by this paper
• Clonal origin of recurrent hepatocellular carcinomas.

  1989cited by this paper

• Serum Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) as a Potential Biomarker for Diagnosis of Hepatocellular Carcinoma

  2024cites this paper
• Updating the Clinical Application of Blood Biomarkers and Their Algorithms in the Diagnosis and Surveillance of Hepatocellular Carcinoma: A Critical Review

  2023cites this paper
• Serum AKR1B10 as an indicator of unfavorable survival of hepatocellular carcinoma

  2023cites this paper
• Clinical value of AKR1B10 in hepatocellular carcinoma: A systematic review and meta-analysis

  2022influential citation
• AKR1B10 inhibits the proliferation and migration of gastric cancer via regulating epithelial-mesenchymal transition

  2021cites this paper
• Fidarestat induces glycolysis of NK cells through decreasing AKR1B10 expression to inhibit hepatocellular carcinoma

  2021cites this paper
• Prognostic value of aldo-keto reductase family 1 member B10 (AKR1B10) in digestive system cancers

  2021cites this paper
• Whole-transcriptome Analysis of Fully Viable Energy Efficient Glycolytic-null Cancer Cells Established by Double Genetic Knockout of Lactate Dehydrogenase A/B or Glucose-6-Phosphate Isomerase

  2020cites this paper
• A Multi-classifier Model to Identify Mitochondrial Respiratory Gene Signatures in Human Cancer

  2019cites this paper
• A Large‐Scale Multicenter Study Validates Aldo‐Keto Reductase Family 1 Member B10 as a Prevalent Serum Marker for Detection of Hepatocellular Carcinoma

  2019cites this paper
• Diagnostic and Prognostic Potential of AKR1B10 in Human Hepatocellular Carcinoma

  2019cites this paper
• Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) overexpression in tumors predicts worse overall survival in hepatocellular carcinoma

  2019cites this paper
• Prognostic significance of AKR1B10 in patients with resected lung adenocarcinoma

  2018cites this paper
• Integrated analysis of the impact of age on genetic and clinical aspects of hepatocellular carcinoma

  2018cites this paper
• Biostatistics mining associated method identifies AKR1B10 enhancing hepatocellular carcinoma cell growth and degenerated by miR-383-5p

  2018cites this paper
• Aldo-Keto Reductases as Early Biomarkers of Hepatocellular Carcinoma: A Comparison Between Animal Models and Human HCC

  2018cites this paper
• Overexpression of Cullin7 is associated with hepatocellular carcinoma progression and pathogenesis

  2017cites this paper